2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Young Adult
PAPER

3300 Clustering of consensus-based core outcomes across diagnoses among survivors of childhood hematologic malignancies

Fanli Yi, PhD, Kirsten Kiri Ness, PhD2, Matthew Ehrhardt, MD3, Stephanie Dixon, MD, MPH4, Kumar Srivastava, PhD5, Fang Kiri Wang, PhD6, Yan Kiri Chen, PhD7, Tara Kiri Brinkman, PhD8, Nicholas Phillips, MD, PhD9, Melissa M. Hudson, MD10, Angela Delaney11, Daniel Kiri Mulrooney, PhD12, Thomas Kiri Merchant, PhD13, Hiroto Inaba, MD. PHD14, Christine Yu, PhD15, Megan Ware16, Wendy Leisenring17, Eric J Chow, MD, MPH18, Lucie Turcotte, MD, MS, MPH19, Ellen Van Der Plas, PhD20, Kevin Oeffinger21, Jordan Marchak22, Claire Snyder23, Paul Nathan, MD24, Leontien C.M. Kremer25, Isaac Rhea26, Johnnie Bass27, Matthew Wilson28, Gregory T. Armstrong29
1 St Jude Children's Research Hospital, Memphis, United States
2 St Jude Children's Research Hospital, Memphis, United States
3 St Jude Children's Research Hospital, Memphis, United States
4 St Jude Children's Research Hospital, Memphis, United States
5 St Jude Children's Research Hospital, Memphis, United States
6 St Jude Children's Research Hospital, Memphis, United States
7 St Jude Children's Research Hospital, Memphis, United States
8 St Jude Children's Research Hospital, Memphis, United States
9 St Jude Children's Research Hospital, Memphis, United States
10 St Jude Children's Research Hospital, Memphis, United States, St Jude Children's Research Hospital, Memphis, United States
11 St Jude Children's Research Hospital, Memphis, United States
12 St Jude Children's Research Hospital, Memphis, United States
13 St Jude Children's Research Hospital, Memphis, United States
14 St Jude Children's Research Hospital, Memphis, United States, St Jude Children's Research Hospital, Memphis, United States
15 St Jude Children's Research Hospital, Memphis, United States
16 Kinesiology, Health Promotion and Recreation, University of North Texas, Texas, United States
17 Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, United States, Seattle, United States
18 Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, United States, Seattle, United States
19 Department of Pediatrics, University of Minnesota, Minnesota, United States
20 Department of Pediatrics, University of Arkansas for Medical Sciences; Division of Hematology/Oncology, Arkansas Children’s Hospital, Arkansas, United States
21 Department of Medicine, Duke University School of Medicine; Division of Hematology/Oncology, Arkansas Children’s Hospital, North Carolina, United States
22 Winship Cancer Institute, Emory University, Atlanta, United States
23 Departments of Medicine, Oncology, and Health Policy & Management, Johns Hopkins School of Medicine and Bloomberg School of Public Health, Baltimore, United States., Baltimore, United States
24 Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Canada, Toronto, Canada
25 University of Utrecht, Utrecht, Netherlands
26 Division of Cardiology, University of Tennessee Health Science Center, Memphis, United States, Memphis, United States
27 Rehabilitation Service, St Jude Children’s Research Hospital, Memphis, United States., Memphis, United States
28 St Jude Children's Research Hospital, Memphis, United States
29 St Jude Children's Research Hospital, Memphis, United States

Background

To promote the reproducibility of outcome ascertainment, the International Childhood Cancer Outcome Project (ICCOP) established 24 core outcomes (COs) for childhood cancer survivors through a Delphi consensus process. However, real-world prevalence and co-occurring patterns have not been systematically evaluated in large survivor cohorts. We estimated the prevalence and clustering of 8 COs defined by ICCOP for leukemia/lymphoma, excluding physical/psychosocial aspects of quality of life, using SJLIFE.

 

Methods

COs were defined as present/absent using the modified Common Terminology Criteria for Adverse Events (CTCAE) definitions previously established in SJLIFE, based on available clinical and laboratory data. Outcomes included overweight/obesity (2-20 years: BMI≥85th percentile;≥ 20 years: BMI> 25 kg/m2), subsequent malignant neoplasms (SMN, grades 3-4), subfertility (male: sperm concentration grades 2-3; female: hypogonadism grade 3; self-reported infertility>1 year), heart failure (HF) (ventricular systolic dysfunction/congestive heart failure grades 3-4; pulmonary hypertension and hypertension grades 2-4), osteonecrosis (grades 2-4), myocardial infarction (MI, grades 3-4), chronic graft versus host disease (cGVHD) and impaired cognitive function (z-score >1.5 on any Childhood Cancer Survivor Study Neurocognitive subscale). Prevalence at the most recent visit was compared between survivors and community controls, and attributable prevalence fractions (APFs) were estimated. Latent class analysis (LCA) identified clusters of COs.

 

Results

Survivors (N=2672) were 52.7% male, diagnosed at a mean age of 8.7±5.49 years, and followed a mean of 35.9±10.31 years. Primary cancer diagnoses included 58.1% acute lymphoblastic leukemia (ALL), 20.2% Hodgkin lymphoma (HL), 12.5% non-Hodgkin lymphoma (NHL), and 9.2% acute myeloid leukemia (AML).  All survivors had received chemotherapy, including 24.0% cranial radiation, 25.7% chest radiation, and 6.6% allogeneic hematopoietic stem cell transplantation (HSCT). Among survivors, 67.3% were overweight/obesity, 35.3% had subfertility, 31.7% had HF, 20.1% had developed SMNs, 6.6% had osteonecrosis, and 10.7% had MI. Among HSCT recipients, 3.4% had chronic GVHD.

The APF among ALL survivors were 14.8% (95% CI: 9.1%-20.1%) for overweight/obesity, 60.1% (95% CI:51.4%-67.2%) for subfertility, 53.3% (95% CI: 43.4%-61.6%) for HF, 100% for osteonecrosis, and 56.3% (95%CI: 50.9%-61.1%) for impaired cognitive function. APF in AML survivors were 63.7% (95% CI: 53.6%-71.8%) for subfertility, 53.3% (95% CI: 39.2%-64.2%) for HF, and 56.7% (95%CI: 50.0%-62.5%) for impaired cognitive function. APF in HL survivors were 10.1% (95% CI: 2.4%-17.1%) for overweight/obesity, 72.9% (95% CI: 66.8%-77.9%) for subfertility, 66.8% (95% CI: 59.3%-73.0%) for HF, 96.5% (95% CI: 89.0%-98.9%) for MI, and 39.4% (95%CI: 30.1%-47.5%) for impaired cognitive function. APF in NHL survivors were 63.0% (95% CI: 53.3%-70.8%) for subfertility, 62.9% (95% CI: 53.4%-70.4%) for HF, and 42.8% (95% CI: 33.2%-51.0%) for impaired cognitive function.

LCA identified high- and low-burden classes for each diagnostic group. Among ALL survivors, 64% were classified in the low burden class, with prevalent overweight/obesity (58%) and subfertility (22%). In contrast, the high burden class had prevalent overweight/obesity (92.9%), SMN (40.0%), HF (60.4%), and subfertility (49.0%). Among AML survivors, 79% belonged to the low-burden class, in which overweight/obesity (49.1%) was the predominant outcome, while the high-burden class exhibited a higher prevalence of SMNs (37.9%), HF (45.0%), and subfertility (66.6%). For HL, 61% of survivors were assigned to the low-burden class, characterized by overweight/obesity (65.6%) and subfertility (33.9%), whereas the high-burden class showed higher prevalences of HF (71.0%) and subfertility (66.9%), with overweight/obesity remaining common. Among NHL survivors, 63% were classified in the low-burden class, where overweight/obesity (51.9%) and subfertility (27.7%) predominated, while the high-burden class was characterized by overweight/obesity (82.3%), HF (97.3%), and subfertility (45.4%).

 

Conclusion

ICCOP COs are more prevalent among survivors of hematologic malignancies than non-cancer controls, with over a third experiencing a high comorbidity. Future studies are needed to understand whether CO clustering can be used to stratify patients into higher- or lower-intensity surveillance strategies.  

Fanli Yi, PhD: No relevant conflicts of interest to declare.